MX342511B - Metodos y composiciones para tratar la enfermedad de raynaud. - Google Patents
Metodos y composiciones para tratar la enfermedad de raynaud.Info
- Publication number
- MX342511B MX342511B MX2013011662A MX2013011662A MX342511B MX 342511 B MX342511 B MX 342511B MX 2013011662 A MX2013011662 A MX 2013011662A MX 2013011662 A MX2013011662 A MX 2013011662A MX 342511 B MX342511 B MX 342511B
- Authority
- MX
- Mexico
- Prior art keywords
- raynaud
- disease
- compositions
- methods
- phenomenon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472988P | 2011-04-07 | 2011-04-07 | |
| PCT/US2012/032577 WO2012139033A1 (en) | 2011-04-07 | 2012-04-06 | Methods and compositions for treating raynaud's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011662A MX2013011662A (es) | 2013-12-12 |
| MX342511B true MX342511B (es) | 2016-10-03 |
Family
ID=46969575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011662A MX342511B (es) | 2011-04-07 | 2012-04-06 | Metodos y composiciones para tratar la enfermedad de raynaud. |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8940794B2 (OSRAM) |
| EP (1) | EP2693877A4 (OSRAM) |
| JP (1) | JP2014510156A (OSRAM) |
| BR (1) | BR112013025744A2 (OSRAM) |
| CA (1) | CA2838109C (OSRAM) |
| MX (1) | MX342511B (OSRAM) |
| RU (1) | RU2633236C2 (OSRAM) |
| WO (1) | WO2012139033A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009918A1 (en) | 2003-04-02 | 2005-01-13 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods for the treatment of vasospasm |
| EP2693877A4 (en) | 2011-04-07 | 2014-11-19 | Nexmed Holdings Inc | METHOD AND COMPOSITION FOR TREATING RAYNAUD SYNDROME |
| PE20151301A1 (es) | 2013-02-05 | 2015-09-16 | Purdue Pharma Lp | Formulaciones farmaceuticas resistentes a la manipulacion indebida |
| CN109288848A (zh) * | 2018-11-27 | 2019-02-01 | 西安力邦肇新生物科技有限公司 | 前列腺素e1甲酯在制备扩张血管药物中的应用 |
| WO2022032141A1 (en) * | 2020-08-07 | 2022-02-10 | Eicos Sciences, Inc. | Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration |
| WO2025019625A1 (en) | 2023-07-18 | 2025-01-23 | Btg International Inc. | Method of using iloprost for treating frostbite |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029814A (en) | 1975-12-29 | 1977-06-14 | The Upjohn Company | Phenyl-substituted prostaglandin-e type analogs |
| US4212987A (en) | 1976-09-17 | 1980-07-15 | The Upjohn Company | 2,2-Difluoro-PGE1 analogs |
| US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| US4820732A (en) | 1985-10-04 | 1989-04-11 | The Upjohn Company | Method and compositions for reducing dysfunction in angioplasty procedures |
| US4955878A (en) | 1986-04-04 | 1990-09-11 | Biotechnology, Inc. | Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures |
| DE3704825A1 (de) | 1987-02-16 | 1988-08-25 | Froelich Juergen | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung |
| US5219885A (en) | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
| US5082866A (en) | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
| US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
| ES2093774T3 (es) | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
| EP0583482B1 (en) | 1992-02-07 | 1999-12-29 | Kaken Pharmaceutical Co., Ltd. | Remedy for wound or hemorrhoid |
| PT746294E (pt) | 1993-10-07 | 2005-03-31 | Odontex Inc | Promotores de absorcao para formulacoes farmaceuticas topicas |
| US5380760A (en) | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
| US20020165122A1 (en) | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US5952006A (en) | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
| US6414028B1 (en) | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
| US6046244A (en) | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| TW473834B (en) | 1998-05-01 | 2002-01-21 | Ibm | Method of doping a gate and creating a very shallow source/drain extension and resulting semiconductor |
| US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
| US7087240B1 (en) | 1998-06-25 | 2006-08-08 | Lavipharm Laboratories Inc. | Device and method for the treatment of erectile dysfunction |
| US6007824A (en) | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| CA2442479C (en) | 1999-05-13 | 2005-12-13 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin e1 delivery |
| US6118020A (en) | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| US6323241B1 (en) | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US7105571B2 (en) | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| DE60124504T2 (de) | 2000-02-04 | 2007-09-20 | Takeda Pharmaceutical Co. Ltd. | Stabile emulsionszubereitungen |
| AU2002317041A1 (en) | 2002-07-24 | 2004-02-09 | Snp Natural Products Pty Ltd | TOPICAL ANTIINFLAMMATORY PREPARATIONS OF Gamma-TERPINENE |
| JP4332151B2 (ja) | 2002-10-30 | 2009-09-16 | メルク フロスト カナダ リミテツド | ピリドピロリジンおよびピリドインドリジン誘導体 |
| US6841574B2 (en) | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
| US20050181030A1 (en) * | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
| US20050009918A1 (en) | 2003-04-02 | 2005-01-13 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods for the treatment of vasospasm |
| ES2466346T3 (es) * | 2006-10-02 | 2014-06-10 | Techfields Biochem Co. Ltd | Profármacos de prostaglandinas solubles en agua con carga positiva y compuestos relacionados con índices de penetración en la piel muy altos |
| EP2011496A1 (en) | 2007-07-03 | 2009-01-07 | Indena S.P.A. | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
| AR068409A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
| EP2693877A4 (en) * | 2011-04-07 | 2014-11-19 | Nexmed Holdings Inc | METHOD AND COMPOSITION FOR TREATING RAYNAUD SYNDROME |
-
2012
- 2012-04-06 EP EP12767469.5A patent/EP2693877A4/en active Pending
- 2012-04-06 BR BR112013025744A patent/BR112013025744A2/pt not_active Application Discontinuation
- 2012-04-06 CA CA2838109A patent/CA2838109C/en active Active
- 2012-04-06 US US14/110,348 patent/US8940794B2/en active Active
- 2012-04-06 RU RU2013141836A patent/RU2633236C2/ru active
- 2012-04-06 WO PCT/US2012/032577 patent/WO2012139033A1/en not_active Ceased
- 2012-04-06 MX MX2013011662A patent/MX342511B/es active IP Right Grant
- 2012-04-06 JP JP2014504039A patent/JP2014510156A/ja active Pending
-
2015
- 2015-01-07 US US14/591,487 patent/US9517218B2/en active Active
-
2016
- 2016-07-29 US US15/224,098 patent/US9855231B2/en active Active
-
2017
- 2017-12-15 US US15/844,361 patent/US10632086B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10632086B2 (en) | 2020-04-28 |
| RU2633236C2 (ru) | 2017-10-11 |
| US9855231B2 (en) | 2018-01-02 |
| WO2012139033A1 (en) | 2012-10-11 |
| BR112013025744A2 (pt) | 2016-08-16 |
| US20160331761A1 (en) | 2016-11-17 |
| EP2693877A4 (en) | 2014-11-19 |
| EP2693877A1 (en) | 2014-02-12 |
| US8940794B2 (en) | 2015-01-27 |
| MX2013011662A (es) | 2013-12-12 |
| JP2014510156A (ja) | 2014-04-24 |
| CA2838109A1 (en) | 2012-10-11 |
| US9517218B2 (en) | 2016-12-13 |
| US20160081954A1 (en) | 2016-03-24 |
| RU2013141836A (ru) | 2015-05-20 |
| CA2838109C (en) | 2020-06-09 |
| US20180333377A1 (en) | 2018-11-22 |
| US20140200274A1 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| MX2013011662A (es) | Metodos y composiciones para tratar la enfermedad de raynaud. | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| NZ631144A (en) | Compositions and methods for transmucosal absorption | |
| NZ703808A (en) | Topical transdermal dexmedetomidine compositions and methods of use thereof | |
| NZ706108A (en) | Topical ketoprofen composition | |
| BR112013025878A2 (pt) | composição farmacêutica e método para produzir uma composição farmacêutica | |
| MX2009013815A (es) | Compuestos de quinazolinona y metodos de uso para los mismos. | |
| WO2015033302A3 (en) | Fulvestrant compositions | |
| TN2014000001A1 (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| WO2015001163A3 (es) | Nanopartículas lipídicas para la cicatrización de heridas | |
| WO2015003021A3 (en) | Dietary supplements and composition for treating cancer | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| MX2014014070A (es) | Metodos para hacer seguros complejos de coordinacion micelares para el tratamiento de plantas y formulaciones para los mismos. | |
| MX348418B (es) | Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada. | |
| WO2009089366A3 (en) | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators | |
| WO2014015137A3 (en) | Compositions and methods for treating dysproliferative diseases | |
| MX362905B (es) | Tratamiento de combinacion. | |
| MX348147B (es) | Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer. | |
| MX2013010947A (es) | Complejos de galio, composiciones farmacéuticas y métodos de uso. | |
| HK1210966A1 (en) | Misprostol composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |